Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Parabilis Medicines, Inc. (PBLS) had 17 insider filings in the last 90 days, with the most recent on 2026-08-25. The full record for PBLS runs to 17 Form 4 filings, the earliest from 2026-06-11. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying PBLS stock?
14 insider purchases of PBLS were filed in the last 90 days, totaling $441.42M.
How many insiders are selling PBLS stock?
No insider sales of PBLS were filed in the last 90 days.
Where can I see PBLS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks PBLS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow PBLS insider buys?
Create a free InsiderAlpha account and press Watch on this page to add PBLS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
